Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration.
Juan García-Revilla, Antonio Boza-Serrano, Ana M Espinosa-Oliva...
https://pubmed.ncbi.nlm.nih.gov/35859075/Actively Recruiting
Led by Rossignol Medical Center · Updated on 2026-04-14
45
Participants Needed
2
Research Sites
4 weeks
Total Duration
Researchers are evaluating TB006, a monoclonal antibody targeting Galectin-3, in adults with Autism Spectrum Disorder ASD. This study explores whether TB006 can improve core and associated behavioral symptoms by reducing neuroinflammation linked to increased microglial activation. The trial is a Phase 2, multisite, double-blind, placebo-controlled randomized clinical trial with a 14-week treatment phase followed by a 14-week open-label extension for placebo subjects. Participants will be randomly assigned in a 21 ratio to receive either TB006 or a placebo. TB006 is given as an intravenous infusion and is designed to neutralize Galectin-3, which is elevated in individuals with ASD. Those initially receiving placebo will have the opportunity to receive TB006 during the open-label extension. The study measures changes in autism symptoms using various clinical scales over the 14 weeks. During the study, participants will attend regular visits for assessments including Childhood Autism Rating Scores CARS at baseline, week 8, and week 14. Additional evaluations include the NIH Toolbox, Clinical Global Impression Scale, Social Responsiveness Scale, and behavioral checklists. Caregivers will also provide input through questionnaires. Safety monitoring includes vital signs and laboratory tests. Overall participation spans the double-blind phase and potential open-label extension, totaling up to 28 weeks.
CONDITIONS
TB006 for Autism Spectrum Disorder
A
Alina Espinoza
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rossignol Medical Center
Lead Sponsor
Autism Discovery and Treatment Foundation
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | TB006 (investigational) | Placebo | Standard non‑drug behavioral and supportive care |
|---|---|---|---|
| What it is | An investigational monoclonal antibody targeting Galectin‑3, studied for its potential to reduce core and associated symptoms of ASD. | An inactive placebo used for comparison within the randomized trial design. | Behavioral therapies and supportive interventions are the usual care approach for managing symptoms in adults with ASD. |
| Role in the trial | Investigational treatment arm being evaluated against placebo. | Control group receiving placebo to assess efficacy and safety of TB006. | Not part of the trial itself; serves as external context for usual care in adults with ASD. |
| Primary use | Investigated to reduce core ASD symptoms in adults. | Used as control to assess TB006 effects. | Continued application of behavioral and supportive therapies for symptom management. |
| How it is given or performed | Administered as an intravenous immunoglobulin G4 monoclonal antibody infusion. | Administered as a matching placebo infusion under blinded conditions. | Delivered through ongoing behavioral therapies and support strategies as per routine care. |
| Evidence status | Efficacy is under investigation; no published results yet. | Placebo provides baseline comparator; no efficacy expected. | Behavioral and supportive therapies have demonstrated benefit for functional outcomes; no drug effect on core ASD symptoms. |
| Important limitations | Study population is small (estimated 45 adults) and limited to moderate‑severity ASD with stable co‑therapies; generalizability may be limited. | Same limitations apply as for TB006 arm due to shared eligibility and size. | Outside trial, evidence largely comes from observational or expert consensus—not randomized drug‑intervention studies. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 14 weeks
Participants receive TB006 or placebo to assess safety and efficacy in improving core symptoms of Autism Spectrum Disorder.
Visits at Baseline, Week 4, Week 8, Week 12, and Week 14
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Juan García-Revilla, Antonio Boza-Serrano, Ana M Espinosa-Oliva...
https://pubmed.ncbi.nlm.nih.gov/35859075/Abdülbaki Artık, Orhan Kocaman, Halil Kara...
https://pubmed.ncbi.nlm.nih.gov/37547549/Juan I Rodriguez, Janet K Kern
https://pubmed.ncbi.nlm.nih.gov/22874006/Xuexin Wang, Shuping Zhang, Faliang Lin...
https://pubmed.ncbi.nlm.nih.gov/23823143/Rossignol Medical Center
Lead Sponsor
Autism Discovery and Treatment Foundation
Collaborating Sponsor